NEW YORK, August 5, 2026, 08:02 EDT — U.S. stocks traded before the opening bell.
- Adjusted earnings were $2.58 per share, surpassing the analyst forecast of $1.85. Revenue totaled $106.1 billion, roughly 6% higher than the consensus.
- CVS increased its 2026 adjusted EPS outlook to a range of $7.90-$8.10, up from its prior estimate of $7.30-$7.50.
- Company range calculations indicate that Health Care Benefits accounted for roughly 98% of the rise in consolidated operating-profit at the midpoint.
CVS Health Corporation NYSE:CVS lifted its full-year forecast following a comprehensive outperformance in the second quarter. The stock was set to open roughly 4% stronger in premarket trading, though early pricing remained tentative.
The main adjustment was limited in scope. Nearly all of the raised operating-profit forecast came from the Health Care Benefits division, which includes Aetna. The annual profit minimum for Health Services remained unchanged.
The quarter surpassed both the previous year and analyst forecasts by significant margins.
| Metric | Q2 2026 | Comparator | Performance |
|---|---|---|---|
| Revenue | $106.10B | $98.92B prior year; $100.03B projected | Up 7.3% YoY; 6.1% higher than projection |
| Adjusted EPS | $2.58 | $1.81 prior year; $1.85 projected | Increase of 42.5% YoY; 39.5% beat over projection |
| Adjusted operating income | $5.16B | $3.81B prior year | Up 35.4% |
| Aetna MBR, lower is better | 87.4% | 89.9% prior year; 90.03% projected | 250 basis points lower YoY |
Health Care Benefits posted an 85.5% rise in adjusted operating income to $2.43 billion. The medical benefit ratio improved by 250 basis points, supported by pricing in government plans and tighter Medicare cost management.
A portion of the increase was retrospective. CVS said $500 million of MBR outperformance came from adjustments to prior-year estimates, such as risk adjustment and favorable development. That constrains the clarity of the ongoing run-rate.
The guidance shifted across each major consolidated line.
| 2026 measure | Previous guidance | New guidance | Increase |
|---|---|---|---|
| Revenue minimum | $405.0B | $414.0B | $9.0B |
| Adjusted operating income | $15.53-$15.87B | $16.58-$16.92B | $1.05B at midpoint |
| Adjusted EPS | $7.30-$7.50 | $7.90-$8.10 | $0.60 at midpoint |
| Operating cash-flow minimum | $9.5B | $11.5B | $2.0B |
The revised $8.00 EPS midpoint is 7.4% higher than the analyst consensus prior to the report. The boost in cash flow also provides CVS with additional flexibility to pay down debt or invest further.
The breakdown by segment reveals the source of the recent profit.
| Segment measure | Previous guidance | New guidance | Shift |
|---|---|---|---|
| Health Care Benefits adjusted operating income | $4.00-$4.34B | $5.03-$5.37B | Midpoint up $1.03B |
| Health Services adjusted operating income | At least $7.25B | At least $7.25B | No change |
| Pharmacy and Consumer Wellness operating income | At least $6.18B | At least $6.40B | Increase of $220M |
| Health Care Benefits MBR | 90.50% ±50 bps | 89.75% ±25 bps | Midpoint better by 75 bps |
Do not total the segment figures outright. Corporate/Other is excluded, and some segment values listed are minimums.
Health Services continued to expand. Revenue increased by 11.5% to $51.8 billion, and profit climbed 10% to $1.73 billion. However, claims volume rose just around 1%. CVS pointed to some profit from the second half being realized earlier and ongoing challenges in the 340B sector.
Retail pharmacy performance remained stable. Revenue edged up by 0.7%, prescription volume climbed 4.3%, and profit advanced 10.2%. CVS raised the full-year profit minimum for the segment by $220 million.
Chief Executive David Joyner stated the businesses “continue to deliver strong performance.” The figures reveal that this performance translated into guidance at Aetna. Q4 Investments
CVS expanded its GLP-1 offerings in partnership with Eli Lilly and Company NYSE:LLY. Starting in the early fourth quarter, app-based pricing for same-day pickup will be available to qualifying Zepbound and Foundayo patients. MinuteClinic virtual visit fees are now set at $29.
The partnership connects clinic appointments, pharmacy services, and online pricing. While it could boost customer footfall, it does not represent the primary earnings driver at present.
UnitedHealth Group Incorporated NYSE:UNH lifted its outlook in July citing improved control over medical costs. CVS must now contend with increased expectations across the sector.
Risks: Medical utilization remained high throughout the quarter. Prior-year development supported the outperformance, but ongoing 340B challenges and broader macroeconomic pressures may limit gains in the second half.
Repeatability is the next assessment. CVS factored a 75-basis-point MBR increase into the midpoint of its yearly guidance. The stock’s rerating now depends on that metric, instead of retail traffic.
Related articles: NYSE:CVS
